Bronchodilator Drugs - Mexico | Statista Market Forecast

The market for Bronchodilator Drugs market in Mexico is expected to witness a significant growth in revenue.
By the year 2024, the projected revenue is estimated to reach US$197.90m.
This demonstrates the potential for substantial market development in Mexico.
Furthermore, the market is projected to experience a steady annual growth rate (CAGR 2024-2029) of 3.47%, leading to a market volume of US$234.80m by 2029.
This steady growth indicates a promising future for the Bronchodilator Drugs market in Mexico.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue in this market.
In 2024 alone, the projected revenue for Bronchodilator Drugs market United States is estimated to be an impressive US$17.34bn.
This highlights the significance of the United States as a major player in the global Bronchodilator Drugs market.
Mexico's demand for bronchodilator drugs is on the rise due to high pollution levels and prevalent respiratory conditions.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in Mexico to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). These drugs help to relax the muscles around the airways in the lungs, making it easier to breathe.

Customer preferences: Mexican consumers are increasingly preferring bronchodilator drugs that are more effective and have fewer side effects. They are also looking for drugs that are affordable and easily accessible. As a result, many consumers are opting for generic bronchodilator drugs over branded ones.

Trends in the market: The bronchodilator drugs market in Mexico is expected to grow in the coming years due to the increasing prevalence of respiratory diseases in the country. The market is also being driven by the introduction of new drugs that are more effective and have fewer side effects. In addition, the government's efforts to improve healthcare access and affordability are also expected to boost the market.

Local special circumstances: Mexico has a high prevalence of respiratory diseases such as asthma and COPD, which is driving the demand for bronchodilator drugs. The country also has a large population, which makes it an attractive market for pharmaceutical companies. However, the market is also highly competitive, with many local and international players vying for market share.

Underlying macroeconomic factors: Mexico's economy has been growing steadily in recent years, which has led to an increase in disposable income among consumers. This has made healthcare more affordable and accessible, leading to higher demand for bronchodilator drugs. The government's efforts to improve healthcare access and affordability are also expected to boost the market. However, the market is also subject to regulatory risks, as the government has been implementing price controls on drugs to improve affordability for consumers.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.